Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 137 | 35 | 102 |
| Samples | 125 | 34 | 91 |
| Peptides | 55 | 17 | 41 |
Function
CGB2 · Chorionic gonadotropin subunit beta 2
The beta subunit of chorionic gonadotropin (CGB) is encoded by six highly homologous and structurally similar genes that are arranged in tandem and inverted pairs on chromosome 19q13.3, and contiguous with the luteinizing hormone beta (LHB) subunit gene. The CGB genes are primarily distinguished by differences in the 5' untranscribed region. This gene was originally thought to be one of the two pseudogenes (CGB1 and CGB2) of CGB subunit, however, detection of CGB1 and CGB2 transcripts in vivo, and their presence on the polysomes, suggested that these transcripts are translated. To date, a protein product corresponding to CGB2 has not been isolated. The deduced sequence of the hypothetical protein of 132 aa does not share any similarity with that of functional CGB subunits (PMID:8954017). However, a 163 aa protein, translated from a different frame, is about the same size, and shares 98% identity with other CGB subunits. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000359342 | Q6NT52 | 137 | 55 |
Gene Properties
Recurrent Mutations
All 55 amino-acid changes on canonical ENST00000359342 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CGB2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CGB2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Rhabdomyosarcoma | 0/33 0% | 2/171 1% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 23/2534 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Cervical Carcinoma | 1/35 3% | 2/422 0% |
| Other Solid Cancers | 4/94 4% | 6/1515 0% |
| Endometrial Carcinoma | 1/42 2% | 2/612 0% |
| Melanoma | 1/210 0% | 8/1899 0% |
| Neuroendocrine Tumour | 3/154 2% | 0/577 0% |
| Bladder Carcinoma | 2/58 3% | 2/956 0% |
| Colorectal Carcinoma | 3/143 2% | 10/3239 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 7/2550 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Gastric Carcinoma | 3/74 4% | 3/1809 0% |
| Ovarian Carcinoma | 3/109 3% | 0/998 0% |
| Other Sarcomas | 2/69 3% | 0/699 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 4/1592 0% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 1/1390 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 1/810 0% |
| Neuroblastoma | 1/87 1% | 1/1331 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Pancreatic Carcinoma | 1/89 1% | 1/1611 0% |
| Head and Neck Carcinoma | 0/85 0% | 2/1574 0% |
| Biliary Tract Carcinoma | 1/54 2% | 0/950 0% |
| Kidney Carcinoma | 1/85 1% | 1/1862 0% |
| Breast Carcinoma | 0/144 0% | 3/3264 0% |
| Glioma | 0/52 0% | 2/2127 0% |
| Hepatocellular Carcinoma | 0/46 0% | 2/2210 0% |
| Other Blood Cancers | 0/61 0% | 1/2725 0% |
Mutation Distribution
Where CGB2 is mutated · all tissues, split by cell line vs tissue
How many mutations in CGB2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 6 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 137 mutations in CGB2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|